Literature DB >> 28074070

Gain of function in Jak2V617F-positive T-cells.

G Nishanth1, D Wolleschak2, C Fahldieck2, T Fischer2, A Mullally3, F Perner2,4,5, T M Schnöder4,5, S Just1, F H Heidel4,5, D Schlüter1,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28074070     DOI： 10.1038/leu.2017.6

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors:  F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal:  Leukemia       Date:  2015-08-05       Impact factor: 11.528

2.  Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

Authors:  François Delhommeau; Sabrina Dupont; Carole Tonetti; Aline Massé; Isabelle Godin; Jean-Pierre Le Couedic; Najet Debili; Patrick Saulnier; Nicole Casadevall; William Vainchenker; Stéphane Giraudier
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

3.  Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.

Authors:  T S Larsen; N Pallisgaard; M B Møller; H C Hasselbalch
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

4.  JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Authors:  Sowmya Parampalli Yajnanarayana; Thomas Stübig; Isabelle Cornez; Haefaa Alchalby; Kathrin Schönberg; Janna Rudolph; Ioanna Triviai; Christine Wolschke; Annkristin Heine; Peter Brossart; Nicolaus Kröger; Dominik Wolf
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

5.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

6.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

7.  Ly6G+ neutrophils are dispensable for defense against systemic Listeria monocytogenes infection.

Authors:  Chao Shi; Tobias M Hohl; Ingrid Leiner; Michele J Equinda; Xiaozhou Fan; Eric G Pamer
Journal:  J Immunol       Date:  2011-10-05       Impact factor: 5.422

8.  Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice.

Authors:  Y Zhan; G J Lieschke; D Grail; A R Dunn; C Cheers
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

9.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Authors:  Maria Kleppe; Minsuk Kwak; Priya Koppikar; Markus Riester; Matthew Keller; Lennart Bastian; Todd Hricik; Neha Bhagwat; Anna Sophia McKenney; Efthymia Papalexi; Omar Abdel-Wahab; Raajit Rampal; Sachie Marubayashi; Jonathan J Chen; Vincent Romanet; Jordan S Fridman; Jacqueline Bromberg; Julie Teruya-Feldstein; Masato Murakami; Thomas Radimerski; Franziska Michor; Rong Fan; Ross L Levine
Journal:  Cancer Discov       Date:  2015-01-08       Impact factor: 39.397

10.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Authors:  Ann Mullally; Steven W Lane; Brian Ball; Christine Megerdichian; Rachel Okabe; Fatima Al-Shahrour; Mahnaz Paktinat; J Erika Haydu; Elizabeth Housman; Allegra M Lord; Gerlinde Wernig; Michael G Kharas; Thomas Mercher; Jeffery L Kutok; D Gary Gilliland; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743
View more
  5 in total

Review 1.  The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.

Authors:  Qin Xu; Xuexiao Jin; Yu Jiang; Xin Dang; Yongmei Han
Journal:  Clin Rheumatol       Date:  2020-07-16       Impact factor: 2.980

Review 2.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

Review 3.  Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.

Authors:  Florian Perner; Caroline Perner; Thomas Ernst; Florian H Heidel
Journal:  Cells       Date:  2019-08-08       Impact factor: 6.600

Review 4.  Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities.

Authors:  Chiara Caprioli; Iman Nazari; Sara Milovanovic; Pier Giuseppe Pelicci
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 5.738

Review 5.  Clonal hematopoiesis and nonhematologic disorders.

Authors:  Siddhartha Jaiswal
Journal:  Blood       Date:  2020-10-01       Impact factor: 25.476
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.